Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details Narrative)

v3.21.1
Commitments and Contingencies (Details Narrative) - USD ($)
1 Months Ended 12 Months Ended
Apr. 30, 2017
Dec. 31, 2020
Dec. 31, 2018
Number of warrants     6,000
Average remaining term in years     5 years
Exercise price per share     $ 1.00
License Agreement [Member] | QSAM Therapeutics Inc [Member]      
Payments for milestone $ 60,000    
Other expense reimbursements $ 150,000 $ 60,000  
Equity method investment ownership percentage 5.00%    
Royalty percentage 4.50%    
Total cost,involved in connection with license   120,000  
License Agreement [Member] | QSAM Therapeutics Inc [Member] | Drug Development Costs Paid to Service Providers [Member]      
Total cost,involved in connection with license   $ 86,943  
License Agreement [Member] | QSAM Therapeutics Inc [Member] | Maximum [Member]      
Royalty percentage 50.00%    
Services Agreement [Member]      
Number of warrants     6,000
Average remaining term in years     5 years
Exercise price per share     $ 1.00